Thanks to its strong balance sheet following the out-licensing deal with Janssen in May 2015, Achillion appears to be well positioned to see its home-grown Factor-D program at least through the mid-stages of a clinical development program. Janssen’s equity purchase has helped to provide the financial muster needed for the company to invest in its early-stage small molecule therapeutics research platform, with its complement Factor D program at the forefront and on the verge of clinical
26 Jan 2016
Moving ahead with Factor-D in rare diseases
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Moving ahead with Factor-D in rare diseases
- Published:
26 Jan 2016 - Author:
-
Pages:
6
Thanks to its strong balance sheet following the out-licensing deal with Janssen in May 2015, Achillion appears to be well positioned to see its home-grown Factor-D program at least through the mid-stages of a clinical development program. Janssen’s equity purchase has helped to provide the financial muster needed for the company to invest in its early-stage small molecule therapeutics research platform, with its complement Factor D program at the forefront and on the verge of clinical